In 187 patients with type 2 diabetes and fatty liver disease, oral semaglutide significantly reduced liver stiffness and improved metabolic markers over 6 months compared to dapagliflozin.
8.07 → 6.51 kPa liver stiffnessOral semaglutide significantly reduced liver stiffness — a marker of fibrosis — over 6 months in patients with diabetes and fatty liver disease (p<0.001)
What the researchers found
Oral semaglutide significantly reduced liver stiffness (8.07 ± 2.90 → 6.51 ± 3.09 kPa, p<0.001) measured by VCTE at 6 months. Both groups showed reduced BMI, waist circumference, and waist-to-hip ratio. Semaglutide showed notable HbA1c decrease (p-value referenced). Both were add-on to metformin.
Why it matters
Fatty liver disease affects up to 70% of type 2 diabetes patients and is a growing cause of liver transplantation. Finding that oral semaglutide significantly reduces liver stiffness — a marker of fibrosis progression — provides evidence for choosing GLP-1 agonists over SGLT2 inhibitors when liver health is a clinical priority.
The numbers in context
Comparison focused on patients with both T2DM and MASLD/MASH. MASLD is associated with cirrhosis and hepatocellular carcinoma risk.
How the study worked
Prospective cohort study of 187 patients with T2DM at a single center. 95 patients received oral semaglutide and 92 received dapagliflozin, both added to metformin. Liver assessment by vibration-controlled transient elastography (VCTE) for steatosis and fibrosis at baseline and 6 months. Anthropometric and metabolic parameters measured.
Who was studied
Patients with type 2 diabetes and metabolic fatty liver disease
What this study cannot tell us
Non-randomized design with potential selection bias between treatment groups. Single center in Romania may limit generalizability. 6-month follow-up is relatively short for assessing liver outcomes. VCTE is an indirect measure of fibrosis — liver biopsy remains the gold standard. The abstract mentions a significant p-value for HbA1c but doesn't clearly report the value.
How to read the evidence
Moderate evidence from a prospective cohort study with appropriate objective outcome measures (VCTE). Strengthened by the comparative design but limited by non-randomization.
When this study was published
Published in 2024, contributing real-world evidence as semaglutide is actively being evaluated for MASH treatment in Phase 3 trials.
The bigger picture
The intersection of diabetes, obesity, and liver disease represents one of the largest unmet needs in medicine. GLP-1 receptor agonists are emerging as uniquely positioned to treat all three conditions simultaneously. Semaglutide is already being studied specifically for liver fibrosis (MASH) treatment, and this real-world data supports its liver benefits.
Questions still open
- Does oral semaglutide's liver benefit persist beyond 6 months and translate to reduced liver-related clinical events?
- Would combining semaglutide with dapagliflozin provide additive liver benefits?
Common questions
What is MASLD and why does it matter for diabetes patients?
What does liver stiffness measurement tell us?
Read the original research
New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.
Diagnostics (Basel, Switzerland), 14(14)
Citation
Stratina, Ermina; Stanciu, Carol; Nastasa, Robert; Zenovia, Sebastian; Stafie, Remus; Rotaru, Adrian; Cuciureanu, Tudor; Muzica, Cristina; Sfarti, Catalin; Girleanu, Irina; Minea, Horia; Petrea, Oana; Huiban, Laura; Chiriac, Stefan; Singeap, Ana-Maria; Vlad, Oana; Cojocariu, Camelia; Trifan, Anca. (2024). New Insights on Using Oral Semaglutide versus Dapagliflozin in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease.. Diagnostics (Basel, Switzerland), 14(14). https://doi.org/10.3390/diagnostics14141475